Filing Summary
Issuer mismatch: The supplied 10-Q is for Priveterra Acquisition Corp., a blank-check company, not AEON Biopharma, Inc. It covers the quarter ended March 31, 2021. The filing provides no AEON Biopharma financial information.
Business Context and Period
Priveterra was formed to pursue a business combination and had not begun operations or generated operating revenue. It completed its IPO on February 11, 2021, selling 27.6 million units at $10 each for $276.0 million gross proceeds, and separately raised $7.82 million from private placement warrants.
Financial Results and Liquidity
- Quarter results: Net income was $6.32 million, driven mainly by a $7.17 million non-cash gain from the change in warrant fair value and $8,319 of trust-account interest. Formation and operating costs were $200,863; IPO transaction costs charged to earnings were $655,046.
- Revenue and margins: No operating revenue; margins are not meaningful for this pre-combination SPAC.
- Cash flow: The filing reports $554,518 of net cash used in operating activities, $276.0 million invested in the trust account, $278.0 million provided by financing activities, and $1.44 million ending cash. The cash-flow statement’s displayed signs and labels are not fully clear in the supplied text.
- March 31 balance sheet: Total assets were $278.15 million, including $276.01 million in the trust account; current liabilities were $467,992; total liabilities were $20.99 million, including $10.86 million of warrant liabilities and $9.66 million of deferred underwriting discount. Redeemable shares of $251.96 million were classified as temporary equity. Stockholders’ equity was $5.00 million.
- Liquidity: Management reported approximately $1.4 million in operating cash and $1.7 million in working capital, and believed available working capital and borrowing capacity would meet needs through a business combination or one year from the filing.
Changes, Outlook, and Risks
- There is no comparable prior-year quarterly operating period in the filing; the company began the quarter with no IPO proceeds and closed its IPO during February. At December 31, 2020, total assets were $81,000 and total liabilities were $59,588.
- Following SEC staff guidance issued April 12, 2021, the company revised its warrant accounting: warrants were reclassified from equity to derivative liabilities and remeasured at fair value. The $7.17 million fair-value gain boosted reported quarterly income; future remeasurement may produce material, volatile non-cash gains or losses.
- The revision followed a material weakness in internal control over financial reporting. Management said remediation efforts were planned, but offered no assurance they would be effective. The filing concluded disclosure controls were not effective as of quarter-end.
- The company had 24 months from the February 11, 2021 IPO closing—through February 11, 2023—to complete a business combination, or it must wind up and redeem public shares under the stated terms. A $9.66 million deferred underwriting fee is payable only if a combination is completed.
- COVID-19 could adversely affect the company or its search for a target, but the impact was not determinable. Sponsor indemnification for certain trust-account claims is not assured because the sponsor’s ability to pay was not verified.
Investor Verification Priorities
- Confirm the intended issuer: this filing is for Priveterra Acquisition Corp., not AEON Biopharma.
- Review the warrant-liability reclassification, valuation assumptions, and impact of future fair-value changes on earnings.
- Assess progress and effectiveness of remediation for the disclosed material weakness and ineffective disclosure controls.
- Verify available operating liquidity, further working-capital borrowing, and the business-combination deadline and redemption terms.
- Reconcile the cash-flow statement presentation and the filing’s per-share wording, which labels the Class B $0.92 amount as “net loss” in one statement despite reporting net income.